Isabella Ciccone, Associate Editor, NeurologyLive®, has been with the team since September 2022. Follow her on Twitter @iciccone7 or email her at iciccone@mjhlifesciences.com
The Influence of Socioeconomic Status and Diet on Multiple Sclerosis Outcomes: Sarah Levy, PhD
March 11th 2025The assistant professor in the department of neurology at Mount Sinai talked about a recent study that highlighted how socioeconomic status and diet could significantly impact physical and cognitive outcomes in patients with MS. [WATCH TIME: 2 minutes]
A Patient’s Perspective on Progress and Challenges in NMOSD Treatment Advances: Sumaira Ahmed
March 3rd 2025The founder and executive director of the Sumaira Foundation talked about how the landscape of NMOSD treatment has drastically improved with FDA-approved therapies, while noting that accessibility and awareness remain significant challenges. [WATCH TIME: 4 minutes]
Recognizing and Investigating the Prodromal Phase in MS and NMOSD: Dalia Rotstein, MD, MPH
March 2nd 2025The assistant professor of medicine at the University of Toronto talked about emerging research on how prodromal symptoms may aid in the early identification of multiple sclerosis and neuromyelitis optica spectrum disorder. [WATCH TIME: 6 minutes]
Investigating Immune Cell Signatures in Multiple Sclerosis Progression: Stephanie Zandee, PhD
March 1st 2025At the 2025 ACTRIMS Forum, the assistant professor of neuroimmunology at McGill University talked about examining immune cell signatures to track disease worsening in multiple sclerosis. [WATCH TIME: 4 minutes]
Paving the Way for Autoimmune Neurology Treatment With CAR T-Cell Therapy: Amanda Piquet, MD, FAAN
February 28th 2025The autoimmune neurology program director at the University of Colorado talked about the emerging use of CAR T-cell therapy, a breakthrough from oncology, now being explored in autoimmune neurologic diseases like multiple sclerosis. [WATCH TIME: 3 minutes]
Unraveling Smoldering Multiple Sclerosis and Progressive Disability: Bruce Bebo, PhD
February 27th 2025The executive vice president of research at National MS Society discussed the role of compartmentalized inflammation, microglial interactions, and emerging therapeutic targets in multiple sclerosis. [WATCH TIME: 4 minutes]
Early Phase 1 Trial Data Suggests Therapeutic Potential for PGN-EDODM1 in Myotonic Dystrophy Type 1
February 25th 2025Initial data reported from the FREEDOM-DM1 trial suggest PGN-EDODM1 has dose-dependent effects in patients with DM1, with further results from study cohorts expected in 2025 and 2026.
FAERS Data Analysis Reveals Insights on Safety Profiles of Narcolepsy Treatments
February 23rd 2025A recent analysis identified potential safety concerns associated with pitolisant, sodium oxybate, solriamfetol, and modafinil, highlighting distinct adverse event profiles for each narcolepsy treatment.
Nuances in Thrombectomy Techniques and Anesthesia Use for Stroke: J Mocco, MD, MS
February 23rd 2025The director of the Cerebrovascular Center at Mount Sinai discussed how results from the ESCAPE-MeVO trial highlight the impact of anesthesia rates, thrombectomy techniques, and the need for rigorous clinical trials to minimize bias. [WATCH TIME: 3 minutes]
The Rationale Behind Recently Approved AXS-07 Combination Therapy for Migraine: Stewart Tepper, MD
February 21st 2025The professor of neurology at the Geisel School of Medicine at Dartmouth talked about how the combination therapy involving meloxicam and rizatriptan may provide a more effective approach to treating migraine. [WATCH TIME: 6 minutes]